1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy

2023 Activity indicators

  • 1 competitive European H2020 project: RESILIENCE
  • 3 public competitive projects led: ISCIII
  • 3 private projects led 
  • 152 clinical studies led
  • 42 publications
  • IF: 404.51
  • Q1 publications: 22 (52%)
  • D1 publications: 11 (26%)
  • 4 thesis
  • 1 award
  • Translations: 1 protocol of use (SEHH), 3 clinical practice guides implemented in the HURYC and 1 guide of recommendations
  • Evaluators of projects from national institutions: 3 PI
  • Editorial committee members: 1 PI
  • Impact on society: 2 actions (II Conference of the Advanced Therapies Network of the CAM and hosting of 18 Mexican haematologists (Preceptorship Visit))
  • 1 hosted visitor and 3 months stay:
    • Universidad Politécnica de Madrid
  • 8 months of stay in a foreign center: 
    • Memorial Sloan Kettering cancer center (USA)

Milestones

  1. Clean Room in the process of validation for CAR-T production. Collaboration with Hospital Clínic for the decentralised production of CART ARI003 (implementation of scaled and centralised production of viral vectors for the manufacture of varnimcabtagene autoleucel (var-cel) for its commercial development and international expansion (INVECTO). PMPTA22/00093. 
  2. Start of clinical trials with CART therapy for multiple myeloma (CARTITUDE-6), non-Hodgkin's lymphoma (CAR T LEDA), and in collaboration with other specialities multiple sclerosis (CA061) and ovarian carcinoma (SURPASS-3). 
  3. Award of a research project in the call for proposals of the National Plan (ISCIII), led by Dr. Luna de Abia, entitled: 'Infection in solid organ transplant recipients: correlation with immune function. Identification of predictive biomarkers and evaluation of feasibility with CD45RAneg cell therapy' (PI23/01924). Integration in the FORTALECE Project of the IRYCIS/ISCIII which aims to strengthen emerging and established groups through the development of innovative therapies and actions for transfer to the clinic (FORT23/00046). 
  4. García-Gutiérrez V et al. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors. Cancers (Basel). 2023 Feb 7;15(4):1045. doi: 10.3390/cancers15041045. PMID: 36831388. 
  5. García-Gutiérrez V et al. Regular Humoral and Cellular Immune Responses in Individuals with Chronic Myeloid Leukemia Who Received a Full Vaccination Schedule against COVID-19 (Respuestas inmunes humorales y celulares regulares en individuos con leucemia mieloide crónica que recibieron un programa completo de vacunación contra COVID-19). Cancers (Basilea). 2023 Oct 20;15(20):5066. doi: 10.3390/cancers15205066. PMID: 37894433.

Networks and alliances